Top of this page
Skip navigation, go straight to the content

Pipeline

A broad range of molecules in late research and pre-clinical development.

Small molecule drug / NCE

Small molecule drug / NCE

Antibody-based drug / NBE

Antibody-based drug / NBE



CNS Indications Phase 1 Phase 2 Phase 3 Filed
Neupro®advanced Parkinson's disease (U.S.)phase 4
Neupro®
restless legs syndrome (U.S.)phase 4
Vimpat®
epilepsy - monotherapy (U.S.)phase 3 half
brivaracetamepilepsy - adjunctive therapy
phase 2
Vimpat®epilepsy - monotherapy (EU)
phase 2
Vimpat®epilepsy - paed. adjunctive therapy1
phase 2 half
Vimpat®epilepsy - adjunctive therapy PGTCS2
phase 2 half
UCB0942epilepsy refactory
phase 1 half
Immunology Indications Phase 1 Phase 2 Phase 3 Filed
Cimzia®rheumatoid arthritis (Japan) phase 3 half
Cimzia®psoriatic arthritisphase 3 half
Cimzia®ankylosing spondylitisphase 3 half
epratuzumabsystemic lupus erythematosusphase 3 half
Cimzia®juvenile rheumatoid arthritis
phase 2
CDP7851fracture healingphase 2 half
CDP7851post-menopausal osteoporosisphase 2 half
olokizumabrheumatoid arthritis
phase 1
CDP7657systemic lupus erythematosusphase 1 half
1. Paediatric 2-17 years
2. Primary generalised tonic clonic seizures